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Background. Diabetes is a leading cause of end-stage renal
disease (ESRD). The purpose of this study is to assess the risk
factors for renal replacement therapy (RRT) in the Early Treat-
ment Diabetic Retinopathy Study (ETDRS).
Methods. We examined demographic, clinical, and laboratory
characteristics of the 2226 subjects with complete laboratory
data enrolled in the ETDRS. The primary renal variable evalu-
ated was the time to development of renal replacement therapy,
defined as the need for dialysis or transplantation. Multivariable
Cox proportional hazards regression was used to assess risk fac-
tors for type 1 and type 2 diabetes separately.
Results. The 5-year estimated incidence of RRT in the entire
ETDRS population was 10.2% and 9.8% for patients with type
1 and type 2 diabetes, respectively. Of those patients with com-
plete data, 127 of 934 (14%) of patients with type 1 diabetes, and
150 of 1292 (12%) patients with type 2 diabetes required RRT
during the study. Baseline risk factors common to type 1 and
type 2 diabetes included elevated total cholesterol, and serum
creatinine; and low serum albumin and anemia. Other risk fac-
tors significant in type 1 diabetes included body mass index
(BMI), shorter duration of diabetes, elevated hemoglobin A1c
(HbA1c), elevated systolic blood pressure, and the development
of proliferative diabetic retinopathy. Risk factors significant in
type 2 diabetes, but not type 1 diabetes, included younger age,
proteinuria, and elevated triglycerides.
Conclusion. In this study, major modifiable risk factors such
as hypertension, dyslipidemia, and hyperglycemia were found
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to be predictive of RRT. Other predictors were markers of vas-
cular pathology and inflammation, proteinuria, hypoalbumine-
mia, and increased serum creatinine. Controlled clinical trials
with treatment strategies that improve serum lipid levels, sys-
temic blood pressure, glycemic control, and markers of inflam-
mation may be important in furthering our knowledge on the
pathogenesis of diabetic complications such as nephropathy and
ESRD.
Diabetes continues to be the leading cause of end-stage
renal disease (ESRD) requiring renal replacement ther-
apy (RRT) in the United States. Approximately 187,000
cases, or 44% of all cases of ESRD, can be attributed to
type 1 (6%) and type 2 (38%) diabetes [1]. Over the next
10 years, the number of patients with diabetes and ESRD
is expected to double, causing a significant increase in
the burden of care for this population of patients [2].
Therefore, the identification of modifiable factors that
might prevent or slow the progression of end-stage dia-
betic nephropathy has become increasingly important.
In patients with type 1 diabetes, renal impairment is
rarely present at the time of diagnosis, but the preva-
lence rises to approximately 20% after 20 to 25 years of
diabetes [3]. The prevalence of nephropathy at diagnosis
of type 2 diabetes is 5% to 10% and the cumulative in-
cidence of nephropathy has been reported to be 25% to
60% after 20 years of diabetes [4]. Despite the differences
in the prevalence of renal disease at the time of diagnosis
of type 1 and type 2 diabetes, the cumulative incidence
[5] and clinical course of renal dysfunction is similar [4].
With continued renal impairment, the glomerular filtra-
tion rate (GRF) declines and macroalbuminuria ensues,
marking the early stages of the progression to end-stage
renal failure [6]. Recently, the World Health Organiza-
tion (WHO) Multinational Study of Vascular Disease in
Diabetes confirmed the importance of proteinuria and
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retinopathy as markers of renal failure in patients with
type 1 and type 2 diabetes [7].
Persons with diabetes may have nondiabetic glomeru-
lopathies that mimic the clinical picture of diabetic
nephropathy [8]. The presence of retinopathy in patients
with diabetes, however, strongly suggests that diabetes
is the underlying cause of the nephropathy [9]. In per-
sons without retinopathy, the likelihood of finding a non-
diabetic cause of renal disease may be as high as 50%
[10]. The Early Treatment Diabetic Retinopathy Study
(ETDRS) enrolled persons with diabetes and retinopa-
thy to study the therapeutic effects of aspirin and laser
photocoagulation on diabetic retinopathy [11]. Because
all ETDRS participants had some degree of retinopathy,
the etiology of renal disease in this population was most
likely due to diabetes. Thus, the ETDRS provides an ideal
cohort to assess the risk factors for diabetic renal disease.
In this study, we use the ETDRS cohort to identify risk
factors for the future development of ESRD requiring
RTT.
METHODS
Study subjects
Subjects were participants in the ETDRS, a random-
ized clinical trial designed to assess photocoagulation
and aspirin treatment for patients with diabetic retinopa-
thy. From April 1980 through July 1985, the ETDRS en-
rolled 3711 persons aged 18 to 69 years with retinopathy
in each eye that was defined as having either mild,
moderate, or severe nonproliferative diabetic retinopa-
thy (NPDR) or mild to moderate proliferative diabetic
retinopathy (PDR), with or without macular edema. The
exclusion criteria for entry into the ETDRS were systolic
blood pressure >210 mm Hg and/or diastolic blood pres-
sure >110 mm Hg, and severe renal disease defined as
a history of renal transplant or renal dialysis. Due to the
need for long-term follow-up in this clinical trial, patients
with severe renal disease, or an unfavorable prognosis for
5 years, were excluded from participating in the ETDRS.
Eligible patients were randomly assigned to receive ei-
ther 650 mg aspirin or placebo daily. Patients were fol-
lowed for a minimum of 5 years and for as long as 9 years.
At baseline and during follow-up exams of 4-month
intervals, ocular examinations and medical examinations
were performed. The ocular risk factors evaluated in-
clude visual acuity, macular edema status, severity of dia-
betic retinopathy, and the development of proliferative
retinopathy during the study. The patient characteris-
tics included age, gender, race, body mass index (BMI),
blood pressure, duration of diabetes, use of insulin, use of
oral hypoglycemic medications, use of antihypertensive
medications, cigarette smoking, alcohol consumption,
and presence of diabetic neuropathy. Blood pressure was
measured in the right arm, or the left arm if the right arm
could not be used, of the seated patient, and was per-
formed by the certified ETDRS medical examiner in the
clinic. Neuropathy, evaluated by a physician at each clin-
ical center, was assessed by testing vibratory sensation
and assessing the patient for ulcers and previous ampu-
tations secondary to diabetes. Patients were classified as
having type 1 diabetes if their age at diabetes diagnosis
was 30 years or less and they started on continuous insulin
use within 1 year of diagnosis, or their age at diabetes
diagnosis was 40 years or less, they started on continu-
ous insulin within 1 year of diagnosis, and their percent
desirable weight was less than 120%. All others were
classified as having type 2 diabetes. Baseline laboratory
measurements assessed include fasting serum levels of
hemoglobin A1c (HbA1c), total cholesterol, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, triglycerides, fibrinogen, creatinine,
hematocrit, plasma proteins (fibrinogen and albumin),
and urine protein. Urine specimens were tested once at
baseline for urine protein by the dipstick method. After
the first 2709 patients were enrolled the ETDRS proto-
col was modified, discontinuing some baseline laboratory
measures.
Outcome measurement
The primary renal variable evaluated is the time to
RRT and this was evaluated at every follow-up visit,
scheduled at 4-month intervals during the course of the
study. RRT was considered to be present when the pa-
tient had or became a candidate for renal dialysis or renal
transplantation.
Statistical analysis
Kaplan-Meier analyses were used to evaluate the rate
of RRT separately in type 1 and type 2 diabetes in the en-
tire ETDRS population. Categorical and continuous vari-
ables were compared using the chi-square and Student
t test, respectively, for the baseline demographic, clinical,
and laboratory characteristics among the patients with
type 1 or type 2 diabetes, with or without the require-
ment of RRT.
Cox proportional hazards regression was used to es-
timate the associations between demographic, clinical,
and laboratory variables and the time to RRT, within
each of the groups. The fully adjusted, multivariate Cox
regression model was built using a backward stepwise
elimination procedure, with age, gender, and race re-
maining in the model. All demographic, clinical, and lab-
oratory variables were entered initially as continuous
variables if possible. The only exceptions to fitting all
variables in the model was for LDL cholesterol. LDL
cholesterol was highly correlated with total cholesterol
in type 1 (r = 0.90) and type 2 (r = 0.81) diabetes. Be-
cause significant results were identical using either total
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Fig. 1. The Kaplan-Meier probability estimates of renal replacement
therapy in the entire Early Treatment Diabetic Retinopathy Study
(ETDRS) population by type 1 and type 2 diabetes.
cholesterol or LDL cholesterol, we used total cholesterol
and not LDL cholesterol in all analyses. The development
of PDR was analyzed as a time-dependent covariate. The
variables were eliminated from the model in the order
of least significance until all remaining variables were
significant at P ≤ 0.10. Continuous variables that were
significant at the P ≤ 0.01 level were also redefined into
clinically relevant categories, based on recommendations
for clinical treatment recommendations where available
[12, 13]. Furthermore, categories may reveal useful infor-
mation in cases of factors that provide nonlinear contri-
butions to risk estimates. Serum creatinine is reported in
the log form in order to control for the skewed distribu-
tion at baseline. Two-way interactions between relevant
variables were then tested, and no significant terms were
found to remain in the model.
Hazards ratios (HR) and 99% confidence intervals
(CI) for the independent variables were calculated from
the parameter estimates and standard errors in the fi-
nal model. The reason for using a statistically significant
P value of ≤ 0.01 and 99% CI is that these are secondary
analyses, and more stringent criteria are preferred. Statis-
tical analyses were performed using SAS 8.2 for Windows
(SAS Institute Inc., Cary, NC, USA).
RESULTS
Study groups
Of the total ETDRS population (N = 3711), the 5-
year Kaplan-Meier probability estimates of RRT during
the course of the study were 10.2% and 9.8% for pa-
tients with type 1 and type 2 diabetes, respectively (Fig. 1).
These rates resulted in approximately 13.2% of patients
with type 1 diabetes and 11.3% of patients with type 2
diabetes requiring RRT during the entire course of the
study. Baseline characteristics of patients with complete
laboratory data, based on type of diabetes and the de-
velopment of the requirement or the lack of requirement
for RRT, are shown in Table 1. Those subjects with com-
plete baseline data, shown in Table 1, did not significantly
differ from those without complete data with respect to
demographic data (data not shown).
Of the ETDRS participants with complete baseline
data, approximately 14% of patients with type 1 dia-
betes (N = 934) developed the requirement for RRT,
with a mean follow-up time of 6.5 (±1.3) years. Those
that required RRT were more likely to use antihyper-
tensive medications, have proteinuria, have developed
proliferative retinopathy during the study, have higher
levels of HbA1c, systolic blood pressure, total cholesterol,
LDL, triglycerides, and fibrinogen; and have lower levels
of serum albumin and hematocrit.
Of those with type 2 diabetes (N = 1232) and complete
baseline data, approximately 12% developed the require-
ment for RRT, with a mean follow-up time of 5.9 (±1.8)
years. In general, those that required RRT were more
likely to be younger, use insulin daily, not use glucose
lowering medications, have proteinuria, have developed
proliferative retinopathy during the study, have higher
levels of BMI, HbA1c, total cholesterol, triglycerides, fib-
rinogen, and serum creatinine, and have lower levels of
HDL, serum albumin, and hematocrit.
Risk factors for RRT
Statistically significant predictors (P < 0.01) of RRT us-
ing multivariable Cox regression are shown in Table 2 by
type of diabetes. Risk factors are shown as both categori-
cal and continuous variables for comparison. Statistically
significant predictors of the development of severe renal
disease found in subjects with type 1 diabetes include du-
ration of diabetes (HR = 0.94, 99% CI 0.90 to 0.99 per
1-year increment), BMI (HR = 1.14, 99% CI 1.05 to 1.23
per 1 unit decrement), HbA1c (HR = 1.21, 99% CI 1.07
to 1.38 per 1% increase), systolic blood pressure (HR =
1.20, 99% CI 1.04 to 1.39 per 10 mm Hg increase), total
cholesterol (HR = 1.08, 99% CI 1.03 to 1.12 per 0.259
mmol/L increment), serum creatinine (HR = 8.74, 99%
CI 3.17 to 24.06 per unit increment of log 1 lmol/L), serum
albumin (HR = 2.54, 99% CI 1.51 to 4.27 per 10 g/L in-
crement), and anemia (HR = 4.62, 99% CI 1.63 to 13.09).
The development of PDR was also a predictor of RRT
(HR = 2.65, 99% CI 1.40 to 5.02). The hazards model for
patients with type 1 diabetes was also adjusted for age,
race, gender, proteinuria, and alcohol consumption.
Statistically significant risk factors for RRT in type 2
diabetes include age (HR = 1.04, 99% CI 1.01 to 1.07 per
1-year decrement), total cholesterol (HR = 1.04, 99%
CI 1.00 to 1.08 per 0.259 mmol/L increment), triglyc-
erides (HR = 1.01, 99% CI 1.00 to 1.03 per 0.113 mmol/L
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Table 1. Baseline characteristics by diabetes type and development of renal replacement therapy (RRT)a
Type 1 diabetes Type 2 diabetes
Development of RRT Development of RRT
Mean ± SD or % Mean ± SD or %
Absent Present Absent Present
Characteristic (N = 807) (N = 127) P value (N = 1142) (N = 150) P value
Age years 34.1 ± 10.9 33.1 ± 8.9 0.23 56.2 ± 8.3 53.0 ± 10.1 0.0003
Gender female 38.9 42.5 0.44 49.5 46.0 0.42
Race white 93.4 93.7 0.91 68.6 70.0 0.72
Duration of diabetes years 18.7 ± 6.4 17.8 ± 5.6 0.12 13.6 ± 7.0 14.6 ± 6.1 0.051
Daily insulin use 100 100 — 71.1 81.3 0.0085
Use of oral hypoglycemics 0.25 0 — 25.7 14.7 0.0030
Use of antihypertensives 4.1 8.7 0.024 23.2 28.7 0.14
Assigned to aspirin treatment 46.6 48.8 0.64 51.2 52.7 0.74
Body mass index kg/m2 23.6 ± 3.3 22.9 ± 3.6 0.052 28.7 ± 5.8 29.9 ± 6.8 0.040
Hemoglobin A1c % 9.9 ± 2.0 10.9 ± 2.1 <0.0001 9.4 ± 2.2 10.0 ± 2.2 0.0012
Systolic blood pressure mm Hg 127 ± 18 135 ± 21 <0.0001 144 ± 22 147 ± 23 0.086
Total cholesterol mmol/L 5.40 ± 1.18 6.28 ± 1.69 <0.0001 6.01 ± 1.24 6.58 ± 1.94 0.0006
High-density lipoproteins mmol/L 1.33 ± 0.36 1.27 ± 0.36 0.075 1.18 ± 0.32 1.13 ± 0.31 0.037
Low-density lipoproteins mmol/L 3.35 ± 0.95 3.95 ± 1.33 <0.0001 3.68 ± 0.96 3.88 ± 1.48 0.12
Triglycerides mmol/L 1.24 ± 0.82 1.74 ± 0.97 <0.0001 1.93 ± 1.27 2.59 ± 1.94 <0.0001
Fibrinogen g/L 2.58 ± 0.60 3.10 ± 0.85 <0.0001 3.13 ± 0.77 3.52 ± 1.16 <0.0001
Serum creatinine lmol/L 87.5 ± 17.3 106.9 ± 39.8 <0.0001 92.8 ± 23.7 120.9 ± 47.7 <0.0001
Serum albumin g/L 34.3 ± 4.3 30.6 ± 5.1 <0.0001 34.2 ± 4.0 30.9 ± 4.7 <0.0001
Presence of proteinuria 27.6 63.0 <0.0001 25.4 58.0 <0.0001
Hematocrit volume fraction
Males 0.46 ± 0.04 0.44 ± 0.05 0.0002 0.45 ± 0.04 0.42 ± 0.05 <0.0001
Females 0.42 ± 0.03 0.40 ± 0.04 0.0011 0.42 ± 0.04 0.39 ± 0.05 <0.0001
Cigarette smoking
Never 47.2 43.3 0.71 51.1 44.7 0.062
Former 21.7 23.6 33.1 32.0
Current 31.1 33.1 15.9 23.3
Alcohol consumption
Never 42.8 51.2 0.029 69.7 67.3 0.20
<1/day 46.5 44.9 25.0 30.0
≥1/day 10.8 3.9 5.3 2.7
Diuretic use 9.5 18.1 0.0037 33.9 42.7 0.034
Extent of macular edema
None in field 2 62.3 60.6 0.025 30.4 30.7 0.19
None in 1 disc diameter of center 9.3 7.9 9.4 8.0
<1 Disc area in disc diameter of center 20.6 15.8 26.4 34.0
≥1 Disc area in disc diameter of center 7.8 15.8 33.8 27.3
Diabetic retinopathy at baseline
Mild to moderate nonproliferative diabetic retinopathy 55.3 39.4 0.0038 74.6 59.3 0.0002
Severe nonproliferative diabetic retinopathy 17.0 23.6 14.5 20.7
Proliferative diabetic retinopathy 27.8 37.0 11.0 20.0
Developed proliferative diabetic retinopathy during follow-up 63.9 88.2 <0.0001 43.4 58.7 0.0004
Neuropathy
Normal 59.4 49.6 0.11 39.8 28.0 0.0029
Vibratory sense diminished 34.7 44.1 49.0 52.0
Ulceration suspect or present 4.0 5.5 6.7 13.3
Amputation 2.0 0.8 4.5 6.7
aRRT is defined as the need for renal dialysis or transplant.
increment), serum creatinine (HR = 17.49, 99% CI 8.10
to 37.77 per unit increment of log 1 lmol/L), serum al-
bumin (HR = 2.85, 99% CI 1.77 to 4.57 per 10 g/L incre-
ment), proteinuria (HR = 2.43, 99% CI 1.52 to 3.89), and
anemia (HR = 4.12, 99% CI 1.62 to 10.39). The hazards
model for patients with type 2 diabetes was also adjusted
for race, gender, HbA1c, diabetic retinopathy, and neu-
ropathy. Aspirin use, as assigned by the ETDRS trial, had
neither a beneficial nor harmful effect on the develop-
ment of the requirement for RRT in either type 1 or type 2
diabetes.
DISCUSSION
The ETDRS enrolled patients with some degree of
retinopathy at baseline, making it likely that the etiol-
ogy of renal disease in this population was related to
diabetes, rather than some other cause of nephropathy
[9]. The present study showed the baseline risk factors
for RRT common to type 1 and type 2 diabetes in-
clude elevated total cholesterol, elevated serum creati-
nine, low serum albumin, and anemia. Other significant
risk factors associated with type 1 diabetes, but not type
2 diabetes, included BMI, shorter duration of diabetes,
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Table 2. Risk factors for renal replacement therapy (RRT): Results
of the final hazards ratio (HR) modelsa
Type 1 diabetesb Type 2 diabetesc
Characteristic HR (99% CI) HR (99% CI)
Age per 1 year decrement 1.01 (0.98–1.04) 1.04 (1.01–1.07)
Body mass index kg/m2
Per 1 kg/m2 decrement 1.14 (1.05–1.23)
<25 1.00 (—)
25 to <30 0.66 (0.38–1.16)
≥30 0.24 (0.05–1.14)
Duration of diabetes per year 0.94 (0.90–0.99)
Systolic blood pressure mm Hg
Per 10 mm Hg increment 1.20 (1.04–1.39)
<130 1.00 (—)
≥130 1.33 (0.77–2.31)
Hemoglobin A1c %
Per 1% increment 1.21 (1.07–1.38) 1.09 (0.99–1.21)
<7.5% 1.00 (—) 1.00 (—)
7.5% to <9.0% 3.87 (0.27–55.36) 1.34 (0.60–3.04)
9.0% to <10.5% 3.79 (0.27–52.53) 1.39 (0.65–2.99)
10.5% to <12.0% 5.31 (0.38–74.20) 1.72 (0.76–3.89)
≥12.0% 7.43 (0.53–103.84) 1.95 (0.84–4.52)
Total cholesterol mmol/L
Per 0.259 mmol/L increment 1.08 (1.03–1.12) 1.04 (1.00–1.08)
<5.180 1.00 (—) 1.00 (—)
5.180 to <6.216 1.03 (0.53–2.00) 0.73 (0.39–1.37)
≥6.216 2.33 (1.25–4.34) 1.12 (0.62–1.97)
Triglycerides mmol/L
Per 0.113 mmol/L increment 1.01 (1.00–1.03)
<1.695 1.00 (—)
1.695 to <2.260 1.06 (0.55–2.02)
≥2.260 1.59 (0.93–2.69)
Serum creatinine lmol/L
Per unit increment of log 8.74 (3.17–24.06) 17.49 (8.10–37.77)
1 lmol/L
<132.6 1.00 (—) 1.00 (—)
132.6 to 176.8 5.17 (2.28–11.72) 6.13 (3.49–10.79)
≥176.8 10.86 (3.47–34.01) 10.74 (4.36–26.47)
Serum albumin g/L
Per 10 g/L decrement 2.54 (1.51–4.27) 2.85 (1.77–4.57)
≥35.0 1.00 (—) 1.00 (—)
30.0 to <35.0 1.98 (1.01–3.86) 2.21 (1.23–3.99)
<30.0 3.18 (1.55–6.55) 2.74 (1.42–5.28)
Proteinuria present 1.47 (0.85–2.57) 2.43 (1.52–3.89)
Hematocrit
Male >50%, female >44% 1.00 (—) 1.00 (—)
Male 45% to <50%, 1.16 (0.53–2.53) 1.36 (0.61–3.04)
female 40% to <44%
Male 40% to <45%, 1.62 (0.75–3.46) 1.86 (0.85–4.08)
female 34% to <40%
Male <40%, female <34% 4.62 (1.63–13.09) 4.12 (1.62–10.39)
Developed proliferative 2.65 (1.40–5.02)
diabetic retinopathy
aRRT is defined as the need for renal dialysis or transplant. Hazard ratios
(HRs) with P value ≤ 0.01 are shown in bold. HRs not significant at P ≤ 0.01 and
categories presented for comparison. Missing HRs did not make the final model
for that type diabetes.
bIn addition to those variables represented in the column, the final Cox
regression model for type 1 diabetes is also adjusted for race, gender, and alcohol
consumption.
cIn addition to those variables represented in the column, the final Cox
regression model for type 2 diabetes is also adjusted for race, gender, diabetic
retinopathy, and neuropathy.
elevated HbA1c, elevated systolic blood pressure, and the
development of PDR. Risk factors associated with type
2 diabetes, but not type 1 diabetes, included younger age,
proteinuria, and elevated triglycerides.
The WHO Multinational Study of Vascular Disease in
Diabetes (WHO MSVDD) assessed predictors of renal
failure, defined as RRT or nephrogenic causes of death,
in patients with type 1 and type 2 diabetes [7]. Similar
to our results in patients with type 1 diabetes, the WHO
MSVDD showed that systolic blood pressure was associ-
ated with renal failure in type 1 but not type 2 diabetes.
Also consistent with our findings was the finding in the
WHO MSVDD that triglycerides were associated with
renal failure in type 2 but not type 1 diabetes. Protein-
uria was also an important risk factor for renal failure in
both type 1 and type 2 diabetes in the WHO MSVDD.
Unlike our findings, however, the WHO MSVDD did not
find total cholesterol associated with the development of
renal failure.
Proteinuria is a well-known complication and predic-
tor of renal disease. Our findings are consistent with other
studies demonstrating a relationship of proteinuria and
the development of nephropathy in patients with type
1 [14–17] and type 2 [18, 19] diabetes. Other complica-
tions of diabetes, such as retinopathy and neuropathy,
although not statistically significant as independent pre-
dictors at the P ≤ 0.01 level in the multivariable hazards
model for type 2 diabetes, were associated with RRT in
our study. The development of PDR was associated with
the development of RRT in patients with type 1 diabetes,
suggesting a parallel course of these two serious compli-
cations, as seen in another study of diabetic retinopathy
[20].
The present study revealed that increasing levels of
serum creatinine were independently associated with the
requirement for RRT in both type 1 and type 2 dia-
betes. An increasing level of serum creatinine is reflective
of a decreasing GFR. In the natural course of diabetic
renal disease, the progressive decline of GFR is gen-
erally thought to be initiated after the development of
overt nephropathy, or macroalbuminuria [4]. Therefore,
increasing levels of serum creatinine likely reflect a more
severe stage of renal disease in patients with diabetes. Hy-
poalbuminemia was also predictive for RRT in both type
1 and type 2 diabetes, consistent with other reports [21].
The excess loss of albumin through the kidney is likely the
result of diabetic renal disease. Low levels of serum al-
bumin, along with decreased BMI, may also reflect other
systemic maladies such as malnutrition in patients with
renal disease.
The interplay between lipids and nephropathy is be-
coming increasingly recognized, and lipids may indepen-
dently contribute to renal injury in patients with dia-
betes [22]. The findings in our study are consistent with
the findings of a recent study where correlations were
shown between lipid abnormalities and degrees of renal
damage in patients with chronic renal failure [23]. We
present HRs for cholesterol and triglycerides treated as
continuous and categorical data for comparison. These
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categories are based on clinical treatment recommenda-
tions of expert panels [12]. Although the high-risk cat-
egories of total cholesterol were not always statistically
significant predictors of RRT as compared with the low-
est risk category, total cholesterol was a statistically sig-
nificant predictor when treated as a continuous variable.
This discrepancy was likely due to the use of categories
that did not adequately separate subjects into a high-risk
group. It is also important to note that the creation of cat-
egories reduces the power of statistical analyses to detect
differences among groups.
Anemia is a complication described in patients with se-
vere diabetic complications [24, 25] and also found to be
associated with an increased risk of developing PDR [26].
Anemia may be secondary to decreased levels of erythro-
poietin, a protein produced by the peritubular fibroblasts
of the renal cortex that mainly functions to stimulate the
production of red blood cells. The decrease in erythro-
poietin is likely caused by damage to the erythropoietin-
producing fibroblasts, indicating serious renal pathology.
However, anemia has been shown to be present in the
earlier stages of nephropathy [27]. In the present study,
decreased hematocrit was predictive of RRT in both type
1 and type 2 diabetes. Our findings confirm previous re-
port of low hematocrit as a predictor of the progression
of renal insufficiency [28].
One of the more novel findings of this study is the ob-
servation that elevated serum fibrinogen, although not in-
dependently statistically significant at the P ≤ 0.01 level
in the multivariable hazards model for type 2 diabetes,
may be predictive of RRT. After adjusting for age and
gender in the current study, hazards models showed that
fibrinogen was a statistically significant predictor of RRT
in type 1 (HR = 1.21, 99% CI 1.15 to 1.28 per 0.20 g/L in-
crement) and type 2 diabetes (HR = 1.12, 99% CI 1.08 to
1.17 per 0.20 g/L increment). High fibrinogen concentra-
tions have been shown to be associated with macrovas-
cular disease for several decades [29, 30]. A relationship
between diabetic nephropathy and fibrinogen has been
demonstrated with associations between markers of in-
flammatory activity, such as C-reactive protein and fib-
rinogen, with increases in proteinuria in patients with
type 2 diabetes [31]. Although we found fibrinogen to
be a possible risk factor, we cannot distinguish between
the possibility that increased fibrinogen leads to throm-
botic events that contribute to diabetic nephropathy or
the possibility that the increased fibrinogen is an acute
phase reactant or “inflammatory marker” related to dif-
fuse microvascular damage, and is therefore an effect of
the disease rather than a cause.
Some of the limitations of this study should be ac-
knowledged. Proteinuria was evaluated with the dipstick
method. Our study did not differentiate between micro-
and macroalbuminuria at baseline and we are therefore
unable to distinguish risk factors associated with differ-
ent severities of proteinuria. Another limitation of this
study was the inability to determine whether factors pre-
dictive of RRT were causative factors or consequences
of already existent renal disease. For example, while the
presence of proteinuria has been regarded as a marker of
the severity of the glomerular pathology, some investiga-
tors have proposed that proteinuria may play a causative
role in renal damage [32].
There is some debate over the exact criteria for classify-
ing patients as having type 1 or type 2 diabetes. Although
we cannot clearly distinguish between type 1 and type
2 diabetes based on duration of diabetes, BMI, and in-
sulin use, our C-peptide analyses suggest that errors in
classification are low [33]. Our ability to determine the
exact duration of type 2 diabetes is not possible and is
comparable to all other studies of this type.
The generalizability of our study is limited by the fact
that our study population is recruited from major oph-
thalmic clinical centers caring for patients with diabetic
retinopathy instead of general medical clinics caring for
their diabetes. Also, a patient’s need for renal dialysis
or transplant was determined by the patient’s physician,
and not by a standardized protocol. Therefore, the results
of this study may be affected by the different treatment
thresholds maintained by different physicians, and the
availability of organs for transplantation.
In this study, we found that the major modifiable risk
factors associated with RRT are serum lipids, glycemia,
and blood pressure. Better control of hyperglycemia and
hypertension have been demonstrated to have favorable
effects on diabetic retinopathy and nephropathy [34, 35]
but, as yet, no large clinical trials have investigated the
effect of better control of serum lipids on renal disease.
Other baseline factors associated with renal disease in
type 1 and type 2 diabetes included serum creatinine,
proteinuria, hypoalbuminemia, and possibly fibrinogen.
Many of these risk markers are also markers of vascu-
lar pathology and inflammation. Interestingly, the risk
factors for severe renal disease in this study are similar
to the risk factors for high-risk PDR and severe visual
loss in the same population [26]. Therefore, we empha-
size that persons with diabetes and retinopathy should
strictly control modifiable risk factors such as glycemia,
blood pressure, and serum lipids in order to possibly slow
the further development of microvascular complications.
It is tantalizing to propose that treatment of dyslipi-
demia may reduce the risk of diabetic nephropathy. Sev-
eral small trials have attempted to address this question
[36–39] and some have suggested benefit [37, 38]. While
it is unlikely that lipid-lowering trials will choose renal
disease as a primary end point, there are several large
lipid-lowering trials in patients with diabetes that could
consider renal disease as a secondary end point. Simi-
larly, ongoing studies of fibrinogen and other inflamma-
tory markers in cardiovascular disease could also assess
Cusick et al: Risk factors for renal replacement therapy: ETDRS Report No. 26 1179
the effects of therapies that modify these risk factors on
renal events.
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